Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: One target, two diseases

Journal of Immunology

Volumn 194, Issue 11, 2015, Pages 5129-5138

  Blanc, Caroline ^a,b   Togarsimalemath, Shambhuprasad Kotresh ^a,c   Chauvet, Sophie ^a,b   Le Quintrec, Moglie ^a,c   Moulin, Bruno ^d   Buchler, Matthias ^e   Jokiranta, T Sakari ^f   Roumenina, Lubka T ^a   Fremeaux Bacchi, Véronique ^a,g   Dragon Durey, Marie Agne's ^a,c,g  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c HÔPITAL TENON   (France)

^d HÔPITAL DE HAUTEPIERRE   (France)

^e CHU BRETONNEAU   (France)

^f UNIVERSITY OF HELSINKI   (Finland)

^g ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; AUTOANTIBODY; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; FACTOR H AUTOANTIBODY; IMMUNOGLOBULIN G ANTIBODY; NEPHRITIC FACTOR; UNCLASSIFIED DRUG; CFHR1 PROTEIN, HUMAN; CFHR3 PROTEIN, HUMAN; IMMUNOGLOBULIN G; PLASMA PROTEIN;

ADULT; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; BINDING AFFINITY; BINDING SITE; C3 GLOMERULOPATHY; CELL SURFACE; CFHR1 GENE; CFHR3 GENE; CHILD; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; EPITOPE MAPPING; FEMALE; GENE; GENE DELETION; GENETIC ASSOCIATION; GLOMERULOPATHY; HEMOLYTIC UREMIC SYNDROME; HUMAN; MALE; MOLECULAR DYNAMICS; MONOCLONAL IMMUNOGLOBULINEMIA; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CLEAVAGE; SURFACE PLASMON RESONANCE; ADOLESCENT; AGED; ANTAGONISTS AND INHIBITORS; GENETICS; IMMUNOLOGY; KIDNEY DISEASE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; AUTOANTIBODIES; BINDING SITES; BLOOD PROTEINS; CHILD; COMPLEMENT C3B INACTIVATOR PROTEINS; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; EPITOPE MAPPING; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; IMMUNOGLOBULIN G; KIDNEY DISEASES; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84929629467     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1402770     Document Type: Article

References (52)

1. Rodríguez de Córdoba, S., J. Esparza-Gordillo, E. Goicoechea de Jorge, M. Lopez-Trascasa, and P. Sánchez-Corral. 2004. The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 41: 355-367.
2. Wu, J., Y. Q. Wu, D. Ricklin, B. J. Janssen, J. D. Lambris, and P. Gros. 2009. Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat. Immunol. 10: 728-733.
3. Roversi, P., S. Johnson, J. J. Caesar, F. McLean, K. J. Leath, S. A. Tsiftsoglou, B. P. Morgan, C. L. Harris, R. B. Sim, and S. M. Lea. 2011. Structural basis for complement factor I control and its disease-associated sequence polymorphisms. Proc. Natl. Acad. Sci. USA 108: 12839-12844.
4. Bhattacharjee, A., M. J. Lehtinen, T. Kajander, A. Goldman, and T. S. Jokiranta. 2010. Both domain 19 and domain 20 of factor H are involved in binding to complement C3b and C3d. Mol. Immunol. 47: 1686-1691.
5. Kajander, T., M. J. Lehtinen, S. Hyvärinen, A. Bhattacharjee, E. Leung, D. E. Isenman, S. Meri, A. Goldman, and T. S. Jokiranta. 2011. Dual interaction of factor H with C3d and glycosaminoglycans in host-nonhost discrimination by complement. Proc. Natl. Acad. Sci. USA 108: 2897-2902.
6. Morgan, H. P., J. Jiang, A. P. Herbert, D. Kavanagh, D. Uhrin, P. N. Barlow, and J. P. Hannan. 2011. Crystallographic determination of the disease-associated T1184R variant of complement regulator factor H. Acta Crystallogr. D Biol. Crystallogr. 67: 593-600.
7. Pickering, M. C., V. D. D'Agati, C. M. Nester, R. J. Smith, M. Haas, G. B. Appel, C. E. Alpers, I. M. Bajema, C. Bedrosian, M. Braun, et al. 2013. C3 glomerulopathy: consensus report. Kidney Int. 84: 1079-1089.
8. Servais, A., V. Frémeaux-Bacchi, M. Lequintrec, R. Salomon, J. Blouin, B. Knebelmann, J. P. Grünfeld, P. Lesavre, L. H. Noël, and F. Fakhouri. 2007. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J. Med. Genet. 44: 193-199.
9. Fakhouri, F., V. Frémeaux-Bacchi, L. H. Noël, H. T. Cook, and M. C. Pickering. 2010. C3 glomerulopathy: a new classification. Nat. Rev. Nephrol. 6: 494-499.
10. Hou, J., G. S. Markowitz, A. S. Bomback, G. B. Appel, L. C. Herlitz, M. Barry Stokes, and V. D. D'Agati. 2014. Toward a working definition of C3 glomerulopathy by immunofluorescence. Kidney Int. 85: 450-456.
11. Sethi, S., and F. C. Fervenza. 2012. Membranoproliferative glomerulonephritis -a new look at an old entity. N. Engl. J. Med. 366: 1119-1131.
12. Servais, A., L. H. Noël, L. T. Roumenina, M. Le Quintrec, S. Ngo, M. A. Dragon-Durey,M. A. Macher, J. Zuber, A. Karras, F. Provot, et al. 2012. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int. 82: 454-464.
13. Servais, A., L. H. Noël, M. A. Dragon-Durey, M. C. Gübler, P. Rémy, D. Buob, C. Cordonnier, R. Makdassi, W. Jaber, E. Boulanger, et al. 2011. Heterogeneous pattern of renal disease associated with homozygous factor H deficiency. Hum. Pathol. 42: 1305-1311.
14. Noris, M., and G. Remuzzi. 2009. Atypical hemolytic-uremic syndrome. N. Engl. J. Med. 361: 1676-1687.
15. Dragon-Durey, M. A., V. Frémeaux-Bacchi, C. Loirat, J. Blouin, P. Niaudet, G. Deschenes, P. Coppo, W. Herman Fridman, and L. Weiss. 2004. Heterozygous and homozygous factor H deficiencies associated with hemolytic uremic syndrome or membranoproliferative glomerulonephritis: report and genetic analysis of 16 cases. J. Am. Soc. Nephrol. 15: 787-795.
16. Licht, C., S. Heinen, M. Jó zsi, I. Löschmann, R. E. Saunders, S. J. Perkins, R. Waldherr, C. Skerka, M. Kirschfink, B. Hoppe, and P. F. Zipfel. 2006. Deletion of Lys224 in regulatory domain 4 of factor H reveals a novel pathomechanism for dense deposit disease (MPGN II). Kidney Int. 70: 42-50.
17. Wong, E. K., H. E. Anderson, A. P. Herbert, R. C. Challis, P. Brown, G. S. Reis, J. O. Tellez, L. Strain, N. Fluck, A. Humphrey, et al. 2014. Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN. J. Am. Soc. Nephrol. 25: 2425-2433.
18. Dragon-Durey, M. A., C. Loirat, S. Cloarec, M. A. Macher, J. Blouin, H. Nivet, L. Weiss, W. H. Fridman, and V. Frémeaux-Bacchi. 2005. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 16: 555-563.
19. Abarrategui-Garrido, C., R. Martínez-Barricarte, M. López-Trascasa, S. R. de Córdoba, and P. Sánchez-Corral. 2009. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 114: 4261-4271.
20. Józsi, M., S. Strobel, H. M. Dahse,W. S. Liu, P. F. Hoyer, M. Oppermann, C. Skerka, and P. F. Zipfel. 2007. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 110: 1516-1518.
21. Hofer, J., A. R. Janecke, L. B. Zimmerhackl, M. Riedl, A. Rosales, T. Giner, G. Cortina, C. J. Haindl, B. Petzelberger, M. Pawlik, et al; German-Austrian HUS Study Group. 2013. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 8: 407-415.
22. Sinha, A., A. Gulati, S. Saini, C. Blanc, A. Gupta, B. S. Gurjar, H. Saini, S. T. Kotresh, U. Ali, D. Bhatia, et al; Indian HUS Registry. 2014. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 85: 1151-1160.
23. Moore, I., L. Strain, I. Pappworth, D. Kavanagh, P. N. Barlow, A. P. Herbert, C. Q. Schmidt, S. J. Staniforth, L. V. Holmes, R. Ward, et al. 2010. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115: 379-387.
24. Józsi, M., C. Licht, S. Strobel, S. L. Zipfel, H. Richter, S. Heinen, P. F. Zipfel, and C. Skerka. 2008. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 111: 1512-1514.
25. Zipfel, P. F., M. Edey, S. Heinen, M. Józsi, H. Richter, J. Misselwitz, B. Hoppe, D. Routledge, L. Strain, A. E. Hughes, et al. 2007. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 3: e41. Available at: http://journals.plos.org/ plosgenetics/article?id=10.1371/journal.pgen.0030041.
26. Dragon-Durey, M. A., C. Blanc, F. Marliot, C. Loirat, J. Blouin, C. Sautes-Fridman, W. H. Fridman, and V. Frémeaux-Bacchi. 2009. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J. Med. Genet. 46: 447-450.
27. Strobel, S., P. F. Hoyer, C. J. Mache, E. Sulyok, W. S. Liu, H. Richter, M. Oppermann, P. F. Zipfel, and M. Józsi. 2010. Functional analyses indicate a pathogenic role of factor H autoantibodies in atypical haemolytic uraemic syndrome. Nephrol. Dial. Transplant. 25: 136-144.
28. Blanc, C., L. T. Roumenina, Y. Ashraf, S. Hyvärinen, S. K. Sethi, B. Ranchin, P. Niaudet, C. Loirat, A. Gulati, A. Bagga, et al. 2012. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J. Immunol. 189: 3528-3537.
29. Jokiranta, T. S., A. Solomon, M. K. Pangburn, P. F. Zipfel, and S. Meri. 1999. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J. Immunol. 163: 4590-4596.
30. Meri, S., V. Koistinen, A. Miettinen, T. Törnroth, and I. J. Seppälä. 1992. Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis. J. Exp. Med. 175: 939-950.
31. Bridoux, F., E. Desport, V. Frémeaux-Bacchi, C. F. Chong, J. M. Gombert, C. Lacombe, N. Quellard, and G. Touchard. 2011. Glomerulonephritis with isolated C3 deposits and monoclonal gammopathy: a fortuitous association? Clin. J. Am. Soc. Nephrol. 6: 2165-2174.
32. Brackman, D., L. Sartz, S. Leh, A. C. Kristoffersson, A. Bjerre, R. Tati, V. Frémeaux- Bacchi, and D. Karpman. 2011. Thrombotic microangiopathy mimicking membranoproliferative glomerulonephritis. Nephrol. Dial. Transplant. 26: 3399-3403.
33. Lorcy, N., N. Rioux-Leclercq, M. L. Lombard, P. Le Pogamp, and C. Vigneau. 2011. Three kidneys, two diseases, one antibody? Nephrol. Dial. Transplant. 26: 3811-3813.
34. Sethi, S., F. C. Fervenza, Y. Zhang, S. H. Nasr, N. Leung, J. Vrana, C. Cramer, C. M. Nester, and R. J. Smith. 2011. Proliferative glomerulonephritis secondary to dysfunction of the alternative pathway of complement. Clin. J. Am. Soc. Nephrol. 6: 1009-1017.
35. Nozal, P., S. Stroble, M. Ibernon, D. Lopez, P. Sanchez-Corral, S. Rodriguez de Cordoba, M. Jozsi, and M. Lopez-Trascasa. 2012. Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clin Kidney J 5: 133-136.
36. Goodship, T. H., I. Y. Pappworth, T. Toth, M. Denton, K. Houlberg, F. McCormick, D. Warland, I. Moore, E. M. Hunze, S. J. Staniforth, et al. 2012. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol. Immunol. 52: 200-206.
37. Watson, R., S. Lindner, P. Bordereau, E. M. Hunze, F. Tak, S. Ngo, P. F. Zipfel, C. Skerka, M. A. Dragon-Durey, and K. J. Marchbank. 2014. Standardisation of the factor H autoantibody assay. Immunobiology 219: 9-16.
38. Sánchez-Corral, P., C. González-Rubio, S. Rodríguez de Córdoba, and M. López-Trascasa. 2004. Functional analysis in serum from atypical hemolytic uremic syndrome patients reveals impaired protection of host cells associated with mutations in factor H. Mol. Immunol. 41: 81-84.
39. Roumenina, L. T., R. Roquigny, C. Blanc, N. Poulain, S. Ngo, M. A. Dragon-Durey, and V. Frémeaux-Bacchi. 2014. Functional evaluation of factor H genetic and acquired abnormalities: application for atypical hemolytic uremic syndrome (aHUS). Methods Mol. Biol. 1100: 237-247.
40. Sinha, N., and S. J. Smith-Gill. 2002. Electrostatics in protein binding and function. Curr. Protein Pept. Sci. 3: 601-614.
41. Li, Y., H. Li, F. Yang, S. J. Smith-Gill, and R. A. Mariuzza. 2003. X-ray snapshots of the maturation of an antibody response to a protein antigen. Nat. Struct. Biol. 10: 482-488.
42. Manuelian, T., J. Hellwage, S. Meri, J. Caprioli, M. Noris, S. Heinen, M. Jozsi, H. P. Neumann, G. Remuzzi, and P. F. Zipfel. 2003. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Invest. 111: 1181-1190.
43. Roumenina, L. T., C. Loirat, M. A. Dragon-Durey, L. Halbwachs-Mecarelli, C. Sautes-Fridman, and V. Fremeaux-Bacchi. 2011. Alternative complement pathway assessment in patients with atypical HUS. J. Immunol. Methods 365: 8-26.
44. Pechtl, I. C., D. Kavanagh, N. McIntosh, C. L. Harris, and P. N. Barlow. 2011. Disease-associated N-terminal complement factor H mutations perturb cofactor and decay-accelerating activities. J. Biol. Chem. 286: 11082-11090.
45. Perkins, S. J., R. Nan, K. Li, S. Khan, and A. Miller. 2012. Complement factor H-ligand interactions: self-association, multivalency and dissociation constants. Immunobiology 217: 281-297.
46. Barlow, P. N.,G. S. Hageman, and S.M. Lea. 2008. Complement factor H: using atomic resolution structure to illuminate disease mechanisms. Adv. Exp. Med. Biol. 632: 117-142.
47. Zager, U., Š. Irman, M. Lunder, M. Škarabot, I. Muševič, V. Hodnik, G. Anderluh, S. Čučnik, T. Kveder, B. Rozman, and B. Božič. 2011. Immunochemical properties and pathological relevance of anti-b2-glycoprotein I antibodies of different avidity. Int. Immunol. 23: 511-518.
48. Strobel, S., M. Zimmering, K. Papp, J. Prechl, and M. Józsi. 2010. Anti-factor B autoantibody in dense deposit disease. Mol. Immunol. 47: 1476-1483.
49. Chen, Q., D. Müller, B. Rudolph, A. Hartmann, E. Kuwertz-Bröking, K. Wu, M. Kirschfink, C. Skerka, and P. F. Zipfel. 2011. Combined C3b and factor B autoantibodies and MPGN type II. N. Engl. J. Med. 365: 2340-2342.
50. Frémeaux-Bacchi, V., M. T. Guinnepain, P. Cacoub, M. A. Dragon-Durey, L. Mouthon, J. Blouin, P. Cherin, J. Laurent, J. C. Piette, W. H. Fridman, et al. 2002. Prevalence of monoclonal gammopathy in patients presenting with acquired angioedema type 2. Am. J. Med. 113: 194-199.
51. Castelli, R., D. L. Deliliers, L. C. Zingale, E. M. Pogliani, and M. Cicardi. 2007. Lymphoproliferative disease and acquired C1 inhibitor deficiency. Haematologica 92: 716-718.
52. Katzmann, J. A., R. Clark, R. A. Kyle, D. R. Larson, T. M. Therneau, L. J. Melton, III, J. T. Benson, C. L. Colby, A. Dispenzieri, O. Landgren, et al. 2013. Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS. Leukemia 27: 208-212.